menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Improving the Global Management of RA: Focusing on the Individual Patient

Drs. Caballero, Choy, and Fleischmann discuss the patient-unique pathologies that underlie RA, the importance of physician-patient communication in...

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Drs. Caballero, Choy, and Fleischmann discuss the patient-unique pathologies that underlie RA, the importance of physician-patient communication in maintaining treatment compliance as well as the mechanisms of action of the biologics used in managing RA.  Finally, they discuss the new options for RA currently in clinical development.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:
    Carlo V. Caballero-Uribe, MD
    President Elect 2016-18 at PANLAR
    Panamerican League of Associations of Rheumatology
    Professor of Medicine
    Universidad del Norte
    Barranquilla, Colombia

    Dr. Caballero-Uribe has nothing to disclose.

    Ernest Choy, MD, FRCP
    Head of Rheumatology and Translational Research
    Institute of Infection and Immunity
    Director of Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)
    Cardiff University School of Medicine
    Cardiff, United Kingdom

    Dr. Choy receives consulting fees from Amgen, Biogen, Celgene, Hospira, Janssen, Napp, Pfizer, Regeneron, Roche, Sanofi-Aventis, Tonix and UCB, serves as a speaker for BMS, Chugai Pharma, Hospira, Pfizer, Regeneron, Roche, Sanofi-Aventis, and UCB and has contracted research for Pfizer, Roche, and UCB.

    Roy Fleischmann, MD, MACR
    Clinical Professor of Medicine
    University of Texas Southwestern Medical Center
    Medical Director
    Metroplex Clinical Research Center
    Dallas, TX

    Dr. Fleischmann receives consulting fees from and has contracted research for Sanofi Regeneron.

    Reviewers/Planners/Authors:

    • Sean T. Barrett, CHCP has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Lawrence Sherman, FACEHP, CHCP has nothing to disclose.
    • Jennifer Spear Smith, PhD has nothing to disclose.
  • Learning Objectives

    At the conclusion of this educational activity, participants will be better able to:

    • Recognize the patient-unique pathologies that underlie RA
    • Understand the importance of physician-patient communication in maintaining treatment compliance
    • Discuss the mechanisms of action of the biologics used in managing RA
    • Evaluate the potential utility of new options for RA currently in clinical development

     

  • Target Audience

    This activity is designed to meet the educational needs of rheumatologists and other healthcare professionals involved in the diagnosis, management, and long-term oversight of patients with RA.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.